

## Drug Monograph

Drug/Drug **Androgel<sup>®</sup> (testosterone) gel / Androgen Hormone**

Class:

Prepared for: MO HealthNet

Prepared by: Xerox Heritage LLC

**New Criteria**

**Revision of Existing Criteria**

### Executive Summary

**Purpose:** The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

**Dosage Forms:** Androgel<sup>®</sup> (testosterone gel) 1.62% is supplied as 1.25 grams and 2.5 grams unit-dose gel packets containing 20.25 and 40.5 mg of testosterone, respectively.

**Manufacturer:** Abbott Laboratories, North Chicago, IL 60064

**Indications:** Androgel<sup>®</sup> is indicated in adult male patients needing replacement therapy due to congenital or acquired causes of primary hypogonadism or hyogonadotropic hypogonadism.

**Costs:** \$ 11.49 per 1.25 gram packet and \$ 11.81 per 2.5 gram packet of Androgel<sup>®</sup> (testosterone) gel. Wholesale Acquisition Cost

**Summary of Findings:** This drug is being considered for inclusion in the state specific Preferred Drug List as a preferred agent.

**Status Recommendation:**  Prior Authorization (PA) Required  Open Access  
 Clinical Edit  PDL

**Type of PA Criteria:**  Increased Risk of ADE  Preferred Agent  
 Appropriate Indications  Under Solicitation

Prepared By: Mary Jo Curtis, Pharm. D. candidate.  
 Date: November 12, 2012